Insider buying last 90 days
No open-market insider purchases were filed for GRDN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every GRDN insider filing, plotted on the chart in Gekko.Open GRDN in Gekko
NYSE: GRDN
Guardian Pharmacy Services (GRDN) Stock Analysis & Forecast
Oct 12 close
$40.47−0.81 (−2.0%)
Gekko Brief
Oct 12 closeGuardian Pharmacy Services closed at $40.47 on 12 October 2026, -2% on the day. The price sits between the 50-day ($40.92) and 200-day ($37.43) moving averages, inside a 52-week range of $23.14 to $48.33. The GekkoIndex reads 59.7, in the Neutral zone, down 0.4 points over five sessions. Gekko Fair Value is $36.50, so the price is 10.9% above it.
The next earnings report is due on 9 November 2026, 28 days away. Over the last 7 reports the company beat the earnings estimate 5 times, with an average move of 5.9% across the report.
5 firms rate the stock: 5 buy, 0 hold and 0 sell, with a consensus target of $49.86. A typical daily move is about 3.8%, and a typical 20-day move about 8.2%. On the swing-trade checklist, 0 items read supportive and 2 read as a headwind (fair value, earnings risk).
A plain summary of the figures as of the Oct 12, 2026 close.
Guardian Pharmacy Services price vs fair value
Close $40.47200-day averageGekko Fair Value $36.50
Guardian Pharmacy Services quick facts
- Market cap
- $2.56B
- P/E ratio
- 40.4
- Forward P/E
- 30.2
- EPS, TTM
- $1.03
- Revenue, TTM
- $1.46B
- Profit margin
- 4.5%
- Dividend yield
- —
- Beta
- 0.02
- Volume
- 733,188 avg 668,597
- 1-year return
- +70.9%
- Typical daily move
- ±3.8%
- Typical 20-day move
- ±8.2%
- 50-day average
- $40.92
- 200-day average
- $37.43
- Next earnings
- Nov 9
- Shares outstanding
- 63.32M
Guardian Pharmacy Services swing-trade checklist
Guardian Pharmacy Services scores 0 supportive, 2 mixed and 2 headwinds across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
0 supportive2 mixed2 headwinds
- Trendmixed
Averages disagree
Close $40.47 sits between the 50-day ($40.92) and 200-day ($37.43) averages, or the averages disagree.
See the chart - GekkoIndexmixed
59.7, Neutral
Reading 59.7 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
10.9% above
Price is 10.9% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 28 days
Reports on Nov 9, 2026, 28 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Guardian Pharmacy Services stock chart and price history
Guardian Pharmacy Services closed at $40.47 on Oct 12, 2026, +70.9% over the past year, inside a 52-week range of $23.14 to $48.33.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −7.3%
- 3 months
- +2.0%
- 6 months
- +2.5%
- 1 year
- +70.9%
The full GRDN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open GRDN in Gekko
Follow Guardian Pharmacy Services through every session
Put GRDN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track GRDN in GekkoFree for 7 days. No credit card required.
Guardian Pharmacy Services GekkoIndex: the smart money zone
Guardian Pharmacy Services’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 59.7, in the Neutral zone, down 0.4 points over five sessions.
59.7Neutral
Down 0.4 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 1 | Too few readings yet | |||
| Accumulation | 139 | +1.2% | +9.3% | ||
| Neutral (current zone) | 309 | +1.4% | +3.5% | ||
| Distribution | 57 | −1.0% | −2.2% | ||
| Selling | 0 | Not available | |||
Average GRDN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the GRDN price, zone by zone.Track GRDN in Gekko
Is Guardian Pharmacy Services stock overvalued? Gekko Fair Value
Guardian Pharmacy Services trades 10.9% above Gekko Fair Value of $36.50, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Guardian Pharmacy Services shares are worth, recalculated every trading day.
$36.50
Gekko Fair Value, Oct 10, 2026
10.9% Overvalued
At the end of Aug 2026 the price was 0.2% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open GRDN in Gekko
Guardian Pharmacy Services insider and Congress trading
No open-market insider purchases were filed for Guardian Pharmacy Services, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in GRDN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for GRDN, plotted on the chart in Gekko.Open GRDN in Gekko
Buybacks
Guardian Pharmacy Services has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $30.28M
- As a share of market cap
- 1.18%
From company filings.
Guardian Pharmacy Services earnings: next date and track record
Guardian Pharmacy Services reports on Nov 9, 2026 (28 days away), and beat the EPS estimate in 5 of its last 7 reports.
Next earnings report
Nov 9, 2026
28 days away
- EPS estimate
- $0.32
- Revenue estimate
- $365.8M
5 of 7reports beat the EPS estimate
±5.9%average move across the report
3 of 6reports followed by a gain
Share-price move across each report
Last earnings call, Mar 11, 2026 AI summary
- What they said
- Guardian Pharmacy Services reported a strong Q4 and full-year 2025 with revenue and margin expansion driven by organic growth, acquisitions, vaccine program improvements, and plan optimization initiatives. Key 2025 metrics: revenue up 17% to $397.6M (12% organic), script volume +14%, residents served +10% to 205,000, adjusted EBITDA +27% with margins up 50 bps to 7.9%, and a ~$60M increase in cash. Management highlighted disciplined investment in M&A and greenfield startups, improved vaccine economics and reimbursement, plan optimization (higher Medicare Part D mix), and early integration benefits from recent acquisitions in the Pacific Northwest. They acknowledged headwinds including branded inhaler category effects from policy changes (IRA), new public company costs, PBM/payor variability, and acquisition-related margin drag (~90 bps). During Q&A, management reiterated a run rate EBITDA target of roughly $110M and an adjusted EBITDA margin midpoint guidance of ~8.6% for 2026, emphasized durable vaccine profitability improvements, a robust M&A pipeline with a disciplined approach, and potential opportunities from competitor distress (subject to bankruptcy processes). Tone was confident and cautious — executives emphasized strong execution and cash generation while acknowledging industry policy uncertainty and integration risks.
- Guidance
- Management guided to a run rate of approximately $110,000,000 of EBITDA and indicated a 2026 midpoint adjusted EBITDA margin of about 8.6% (driven by low-double-digit adjusted EBITDA growth while revenues remain relatively flat). They also noted they are not projecting certain Q4 one-time positives (PBM payor net positive, increased acuity) into their base.
- Risks flagged
- Risks mentioned include: implementation effects from the Inflation Reduction Act (IRA) and related reimbursing/contracting changes (notably branded inhaler headwind), PBM/payor variability (quarter-to-quarter), acquisition integration drag (greenfield and recent acquisitions dampening margins ~90 bps), new public company costs, potential industry consolidation or competitor bankruptcies (while creating opportunities, also introduce uncertainty), and general cash flow pressures across the long-term care pharmacy industry.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Mar 11, 2026 | $0.37 est $0.27 | $397.6M est $390.0M | −1.1% |
| Nov 10, 2025 | $0.25 est $0.24 | $377.4M est $390.0M | +8.5% |
| Aug 11, 2025 | $0.23 est $0.22 | $344.3M est $344.1M | +13.3% |
| Apr 1, 2025 | $0.19 est $0.22 | $329.3M est $329.4M | +1.3% |
| Mar 27, 2025 | $0.24 est $0.22 | $338.6M est $323.1M | −0.4% |
| Nov 12, 2024 | −$2.00 est $0.19 | $314.4M est $303.1M | −11.0% |
| Aug 28, 2024 | $0.25 est $0.00 | — | — |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Guardian Pharmacy Services stock forecast and analyst price targets
Analysts’ average 12-month price target for Guardian Pharmacy Services is $49.86, +23.2% from the last close, from 5 firms rating the stock in the last 90 days.
$49.86consensus 12-month target, +23.2% from the last close
Now $40.47Avg $49.86
Low $47High $52
Each firm’s latest rating in the last 90 days: 5 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 22 | KeyBanc | $52 | +28.5% |
| Sep 22 | KeyBanc | $52 | +28.5% |
| Sep 21 | Truist Financial | $51 | +26.0% |
| Aug 7 | Bank of America Securities | $47 | +16.1% |
| Aug 7 | Stephens | $50 | +23.5% |
+3.5%average 20-day move after past Neutral readings
±3.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Guardian Pharmacy Services market cap and key statistics
Guardian Pharmacy Services’s market cap is $2.56B, with a P/E ratio of 40.4 and revenue of $1.46B over the last twelve months.
Valuation
- Market cap
- $2.56B
- P/E ratio
- 40.4
- Forward P/E
- 30.2
- EPS, TTM
- $1.03
- Gekko Fair Value
- $36.50
Trading
- Volume
- 733,188
- Avg volume, 20 days
- 668,597
- 52-week high
- $48.33
- 52-week low
- $23.14
- Shares outstanding
- 63.32M
Financials
- Revenue, TTM
- $1.46B
- Profit margin
- 4.5%
- Return on equity
- 30.4%
- Quarterly earnings growth, YoY
- +139.8%
Risk and income
- Beta
- 0.02
- Typical daily move
- ±3.8%
- Typical 20-day move
- ±8.2%
Guardian Pharmacy Services stock news this week
1 headline about Guardian Pharmacy Services from the past week, newest first, each linking to the publisher.
Guardian Pharmacy Services peers
Guardian Pharmacy Services’s 1 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| CVSCVS Health | Accumulation | 44.9% below |
A peer links to its own page where one exists.
Guardian Pharmacy Services stock FAQ
What is Guardian Pharmacy Services’s market cap?
Guardian Pharmacy Services’s market cap is $2.56B at the Oct 12, 2026 close of $40.47, with 63.32M shares outstanding. The shares trade on a P/E ratio of 40.4.
What is the Guardian Pharmacy Services stock forecast?
The consensus analyst 12-month price target for Guardian Pharmacy Services is $49.86, +23.2% from the last close. Of the 5 firms that rated the stock in the last 90 days, 5 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Guardian Pharmacy Services stock overvalued or undervalued?
On Gekko’s estimate Guardian Pharmacy Services is overvalued: the Oct 12, 2026 close of $40.47 is 10.9% above Gekko Fair Value of $36.50. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Guardian Pharmacy Services report earnings next?
Guardian Pharmacy Services is expected to report on Nov 9, 2026 (28 days away). Analysts expect earnings of $0.32 per share on revenue of $365.8M. Guardian Pharmacy Services beat the earnings estimate in 5 of its last 7 reports, moving 5.9% on average across the report.
What is Guardian Pharmacy Services’s 52-week high and low?
Guardian Pharmacy Services’s 52-week high is $48.33 and its 52-week low is $23.14; it closed at $40.47 on Oct 12, 2026, +70.9% over the past year.
Is Guardian Pharmacy Services stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 0 of the 4 items with data read as supportive, 2 as mixed (trend and gekkoindex) and 2 as headwinds (fair value and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Guardian Pharmacy Services the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.